PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.
Table 1: Glucagon-Like Peptide-1 Receptor Agonists

Formulary Agents:

Exenatide (Byetta, Bydureon)
Liraglutide (Victoza)

Nonformulary: None

Step therapy was removed in this subclass

Recommended implementation period: 90 days

Figure 1: Glucagon-Like Peptide-1 Receptor Agonists
30-Day Equivalents in All Points of Service
Table 2: Overactive Bladder Drugs

**Formulary:**
- Step-preferred: tolterodine ER (Detrol LA), oxybutynin ER, oxybutynin IR

**Formulary after a trial of step-preferred agents:** trospium (Sanctura IR (gen), Sanctura ER (gen), tolterodine IR, solifenacin (Vesicare)

**Nonformulary after a trial of step-preferred agents:** fesoterodine (Toviaz), darifenacin (Enablex), oxybutynin (Oxytrol patch), oxybutynin (Gelnique 10%)

All patients (current and new users) must receive a trial of the step-preferred agents (No grandfathering)

Implementation Plan: 90 Days

**Figure 2: 30-Day Equivalents in All Points of Service**
Table 3: Gastrointestinal Oral Antibiotic Drugs (GI-2)

Formulary: metronidazole, vancomycin, neomycin, rifaximin, nitazoxanide, fidaxomicin

Nonformulary: None

Figure 3: Gastrointestinal Oral Antibiotic Drugs (GI-2) Utilization in All Points of Service
Table 4:

**Formulary:**  Boceprevir (Victrelis), Interferon alfa-2b (Intron A), PEG-interferon alfa-2a (Pegasys), PEG-interferon alfa-2b (PEG-Intron), Ribavirin (except Ribapak), Telaprevir (Incivek)

**Nonformulary:**  Interferon alfacon-1 (Infergen), Ribavirin (Ribapak)

Implementation Plan:  60 Days

**Figure 4:** Interferon Utilization in 30-Day Equivalents in All Points of Service
Figure 5: Ribavirin Utilization in 30-Day Equivalents in All Points of Service

Figure 6: DAA Utilization in 30-Day Equivalents in All Points of Service
Table 5: Narcotic Analgesics—High Potency

Formulary: Morphine Sulfate (various forms), Codeine tablets, fentanyl patches, hydromorphone various forms, meperidine tablets, oxycodone (Oxycontin), oxymorphone (Opana)

Nonformulary: Oxycodone Immediate Release Tablets (Oxecta)

Implementation Plan: 60 Days

Figure 7: Narcotic Analgesics Utilization in All Points of Service

![Graph showing narcotic analgesics utilization from 11/30/10 to 10/31/12](image)
### Table 6: Table of Implementation Status of UF Recommendations/Decisions Summary Table

<table>
<thead>
<tr>
<th>Meeting</th>
<th>Drug Class</th>
<th>Nonformulary Medications</th>
<th>Total Beneficiaries Affected (# of patients affected)</th>
<th>Beneficiaries Affected by POS</th>
<th>Implementation Plan</th>
<th>Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov 2012</td>
<td>High Potency Narcotics</td>
<td>oxycodone immediate release tablets (Oxecta)</td>
<td>4 0 4 0 60 days</td>
<td>MTF Retail Mail Order</td>
<td>First Wednesday X days after the decision date</td>
<td>60 days</td>
</tr>
<tr>
<td></td>
<td>Overactive Bladder</td>
<td>fesoterodine (Toviaz), darifenacin (Enablex), oxybutynin (Oxytrol patch), oxybutynin (Gelnique 10%)</td>
<td>All agents are currently nonformulary</td>
<td></td>
<td>90 days</td>
<td>toterodine ER (Detrol LA), oxybutynin ER, oxybutynin IR are step-preferred. ~ 59K will be affected by no grandfathering</td>
</tr>
<tr>
<td></td>
<td>Hep C</td>
<td>Interferon alfacon-1 (Infergen), ribavirin (Ribapak)</td>
<td>185 5 172 8 60 days</td>
<td>MTF Retail Mail Order</td>
<td></td>
<td>60 days</td>
</tr>
</tbody>
</table>
